PPARA and metabolic dysfunction-associated steatohepatitis: In choline-deficient, L-amino acid-defined, high-fat diet-induced NASH in mice, saroglitazar exhibited stronger anti-steatosis efficacy than the selective agents fenofibrate (PPARα) and pioglitazone (PPARγ)28.